Enhertu is currently approved as a second-line treatment for HER2-positive metastatic breast cancer. The new results for the AstraZeneca and Daiichi Sankyo drug in the first-line setting are important because many patients do not live long enough to receive a second-line cancer therapy. The post AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line…
Earlier this month Sachin Jain, CEO of SCAN Health Plan, a nonprofit Medicare Advantage company, provided some refreshing straight talk on what is wrong with MA while stressing that it is far better than traditional Medicare for seniors. The post Medicare Advantage CEO: My Baby is Ugly…(video) appeared first on MedCity News.
Even the most promising medical advancements struggle to take off in real-world settings without clinician buy-in. Here are some key factors that affect clinician adoption and ways healthtech companies can better position their innovations for success. The post Clinician Adoption: How HealthTech Can Overcome Key Barriers appeared first on MedCity News.
In the U.S., many people still struggle to find care, book an appointment, confirm coverage, or get a clear answer on pricing. The impact goes beyond inconvenience, contributing to delayed diagnoses, increased anxiety, and financial stress that harms both patients and the healthcare system. The post The Price is Wrong: We Need to Solve the…
The healthcare investor conference MedCity INVEST, scheduled for May 20-21 at the Willis Tower in Chicago, will spotlight a wide range of topics from GLP-1 drug coverage to investment trends and more. Register today! The post What Are Health Systems’ Strategic Priorities in 2025? appeared first on MedCity News.
The FDA approved Sanofi and Regeneron Pharmaceuticals drug Dupixent as a treatment for the inflammatory skin disorder chronic spontaneous urticaria. The regulatory decision comes two years after the agency turned down an application for the biologic drug in this indication. The post Blockbuster Sanofi & Regeneron Drug Dupixent Notches FDA Nod for an Inflammatory Skin…
Too many women have experienced the impacts of living with gynecological conditions while feeling dismissed and struggling to get care. Women deserve better, and as we collectively challenge outdated norms, we are beginning to see improvement. Still, there’s much more work to be done. The post Women’s Health is Having Its Moment – It’s Time for…
Although the healthcare industry has a long way to go before PGx testing for DPYD and other genes becomes widespread, it’s encouraging that regulatory bodies and professional organizations are making recommendations and raising awareness among healthcare providers. The post Drug-Gene Testing: Key to Safer Cancer Treatment appeared first on MedCity News.
The Trump administration’s steep tariffs on Chinese imports are threatening to further destabilize hospitals’ bottom lines by driving up the cost of essential supplies and exacerbating already fragile supply chains. As providers prepare for higher expenses and potential shortages, experts warn that these policies could wosen care quality and force hospitals to make tough financial…
UnitedHealth Group’s shares fell by over 22% on Thursday after its first quarter earnings. This is largely due to challenges in its Medicare Advantage business. The post Why UnitedHealth Group’s Shares Have Taken a Tumble appeared first on MedCity News.